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In 2009 the seasonal inﬂ  uenza virus was replaced with a 
pandemic H1N1 infection strain (swine ﬂ  u). Since that 
time, numerous reports have surfaced of severe disease 
occurring and resulting in acute lung injury and mor-
tality. Treatment of this infection has involved oselta-
mavir and supportive care. A logical next step would be 
to ﬁ   nd an adjuvant agent that could be of beneﬁ  t  in 
severe disease. To discover this agent, one must ﬁ  rst 
understand the pathogenesis of this unique virus.
In the previous issue of Critical Care, Schouten and 
colleagues attempt to build on the knowledge gained 
about the pathogenesis of H1N1 in a lethal mouse model 
[1]. Th  ese authors ask two questions. Does viral pneu-
monia due to H1N1 cause sytemic and pulmonary activa  -
tion of coagulation and inhibition of ﬁ  brinolysis in the 
lungs similar to what is known to occur in community-
acquired bacterial pneu  monia and acute respiratory 
distress syndrome? If so, does activated protein C (APC) 
– a molecule with anti  coagulant, anti-inﬂ  ammatory and 
proﬁ  brinolytic proper  ties – abrogate this response and 
improve outcome, as is suggested by its eﬀ  ects in patients 
with sepsis due to community-acquired pneumonia [2]?
Th   e results of Schouten and colleagues’ study indicate 
that activation of coagulation and impairment of ﬁ  brino-
lysis does in fact occur during H1N1 infection. Th  ey  also 
corroborate the ﬁ  nd  ings of intense neutrophil inﬂ  ux in 
the lung, pro  longed cytokine storm and diﬀ  use alveolar 
damage as key components of the pathogenesis of the 
infection [3]. APC was able to decrease coagulation 
activation and restore normal ﬁ  brinolysis compared with 
placebo but had marginal eﬀ   ects on cytokine levels, 
pulmonary neutrophil inﬂ  ux and outcome.
Th   e results from this animal study add to the evidence 
that coagulation inhibition per se does not improve out-
come in acute lung injury. A randomized, placebo-
controlled trial of recombinant human APC in 75 
patients with acute lung injury without sepsis demon-
strated no beneﬁ  t of APC with respect to ventilator-free 
days, mortality or lung injury score [4]. A trial of a 
recombinant tissue factor pathway inhibitor in patients 
with severe community-acquired pneumonia demon-
strated no beneﬁ  t (Wunderiak R, et al.,unpublished data).
A possible downside to thrombin inhibition by anti-
coagulation agents is the loss of the ability to wall oﬀ   
infection through ﬁ  brin formation. Fortunately, APC led 
to lower viral load in the lungs. Additionally, inhibition of 
thrombin formation could prevent the activation of throm-
bin activatable ﬁ  brinolysis inhibitor. Activated throm  bin 
activatable ﬁ  brinolysis inhibitor inhibits the chemotactic 
factors C3a and C5a, which could be important for 
prevention of inﬂ  ux of leukocytes into the lung [5]. As 
the authors of the current study mention, mutant variants 
of APC with anti-inﬂ  ammatory properties and little anti-
coagulant activity could be examined in future animal 
studies.
Th   e lack of eﬀ  ect of APC on cytokine production and 
neutrophil inﬂ   ux that is prominent in H1N1 merits 
discussion. Th   e current study’s authors showed that APC 
had no eﬀ   ect on cytokine elaboration or pulmonary 
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monia model and in an endotoxin challenge model in rats 
[6,7].  In vitro models have demonstrated an inhibitory 
eﬀ  ect of APC on cytokine eﬀ  ect with much higher concen-
trations of APC relative to the levels achieved in this study 
[8]. In both a human and a sheep pulmonary endotoxin 
study, recombinant human APC given as a continuous 
infusion of 24 μg/kg/hour was able to decrease the 
inﬁ  ltration of neutrophils into the lung [9,10]. In human 
septic patients and in an intravenous endotoxin challenge 
model in healthy human volunteers, no anti-inﬂ  ammatory 
eﬀ  ects were observed with this dosing strategy [11,12]. 
Th  ese data would suggest that the anti-inﬂ  ammatory 
eﬀ   ects of APC vary by species, by type of infectious 
challenge, by means of APC dosing and by blood con  cen-
trations, such that more information needs to be learned 
with respect to optimized dosing in H1N1 infection. 
Future animal studies with the previously men  tioned APC 
variants with minimal anticoagulant eﬀ  ects would allow 
the authors to push the blood concentration for deter-
mination of the maximal anti-inﬂ  ammatory eﬀ  ect.
Th   e absence of a beneﬁ  t in terms of survival with APC 
treatment in this murine model of H1N1 infection does 
not necessarily predict a lack of beneﬁ  t in human H1N1 
infection. Th   is model was quite severe with 100% lethality, 
while mortality in human H1N1 infection is less than 
20% in severe cases [13,14]. Th   e mice were young, healthy 
and of normal weight, which does not mimic the clinical 
situation in humans. Oseltamavir was not given in this 
model, which could aﬀ   ect the treatment response to 
APC. Upwards of 30% of human patients with H1N1 
develop bacterial pneumonia and severe sepsis in which 
recombinant human APC may still be beneﬁ  cial  [3]. 
Severe human H1N1 infection is complicated by shock in 
30 to 60% of cases and by renal failure in 22% of cases 
[13,14]. Th  is animal model did not monitor organ 
dysfunction, which APC may prevent through PAR-1 
signal ing  [15].
In summary, the jury is still out regarding whether APC 
could potentially play a future role in the management of 
H1N1 infection. Future experiments will need to include 
mice and other species of diﬀ  erent ages, diﬀ  erent infect-
ing doses of H1N1, concomitant oseltamavir treat  ment, 
monitoring and evaluation of hemodynamic and non-
pulmonary organ function, and diﬀ   erent dosages and 
means of administration of APC and APC variants.
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